Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20–29 in the UK

BACKGROUND: Human papillomavirus (HPV) vaccination has been approved in more than 90 countries and is being implemented in many of these. In the UK, vaccination for girls aged 12–13 with catch-up for girls up to age 18 was introduced in 2008, using the bivalent GSK vaccine (Cervarix). METHODS: We mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuzick, J, Castañón, A, Sasieni, P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833241/
https://www.ncbi.nlm.nih.gov/pubmed/20104226
http://dx.doi.org/10.1038/sj.bjc.6605528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833241/
https://www.ncbi.nlm.nih.gov/pubmed/20104226
http://dx.doi.org/10.1038/sj.bjc.6605528

Ejemplares similares